Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64565111 in Type 2 Diabetes
NCT02862431Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efinopegdutide in type 2 diabetes mellitus (T2DM) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. Started Jul 2016; status: terminated.
02
Drugs
efinopegdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02862431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862431.